Breaking News: Cellular Biomedicine Group (
NASDAQ: $CBMG) and #GE Healthcare Life Sciences China Announce
Strategic Partnership to Establish Joint Technology Laboratory to Develop
Control Processes for the Manufacture of CAR-T and Stem Cell Therapies
SHANGHAI, China and CUPERTINO, Calif., April 10,
2017-- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (CBMG or the
Company), a leading clinical-stage biopharmaceutical firm engaged in the
development of immunotherapies for cancer and stem cell therapies for degenerative
diseases and GE Healthcare Life Sciences China, today announced that they have
established a strategic research collaboration to co-develop certain
high-quality industrial control processes in Chimeric Antigen Receptor T-cell
(CAR-T) and stem cell manufacturing. In connection with the
collaboration, a joint laboratory within CBMG`s new Shanghai Zhangjiang
GMP-facility will be established and dedicated to the joint research and
development of a functionally integrated and automated immunotherapy cell preparation
system.
CBMG and GE Healthcare Life Sciences China plan to
develop state-of-the-art automated CAR-T and stem cell manufacturing
capabilities that build upon the accreditation of CBMG`s GMP facilities in
Shanghai, Wuxi and Beijing. The co-development activity will aim to
standardize the delivery of cell manufacturing to potentially improve
throughput, alleviate cost burdens and to minimize variability in cell
production, which may increase the availability of engineered cells upon
commercialization.
This partnership combines CBMG`s scientific expertise
in the manufacturing of CAR-T and stem cell production in China and GE
Healthcare`s renowned expertise in the design and development of innovative
manufacturing technologies for the biopharmaceutical industry.
Recently, CBMG announced that its new Zhangjiang
facility, together with an expanded Wuxi, and Beijing GMP-facilities, will have
a combined 70,000 square feet for development and production. This will enable
CBMG to conduct simultaneous clinical trials for multiple CAR-T and stem cell
product candidates. At full production volumes, these facilities could support
the treatment of up to 10,000 cancer patients and 10,000 knee osteoarthritis
patients per year.
"GE Healthcare`s selection of our facility to
serve as their showcase site in China, credits our GMP stature and
capabilities. Our team of scientists has spent years refining our manufacturing
process to become one of the very few cell therapy companies with fully
in-house integrated chemistry, manufacturing, and controls (CMC) processes for
clinical grade CAR-T cells, plasmid and viral vectors bank production. We
understand that one of the impending barriers to adoption of immuno-oncology
and stem cell therapies is the logistics in manufacturing and we look to take
an expanded role both domestically and potentially globally. We are
pleased to be in a strategic partnership with GE Healthcare and look forward to
showcasing our facilities and the mutual benefit this joint laboratory will
bring," commented Tony Liu, Chief Executive Officer, CBMG.
"Cell therapy as an industry continues to refine
and evolve in China with vast potential to change the ways various diseases are
treated. GE continues investing in technologies and services aimed at the
thriving cell therapy industry with a firm commitment of making these promising
therapies accessible through successful industrialization. We are pleased to
partner with CBMG, a leader in CAR-T and stem cell development in China and to
take advantage of their excellent CMC cell production capabilities.
Collaboration with ambitious partners like CBMG who share our vision is
necessary for advancing innovation and delivering comprehensive manufacturing
solutions for cell and regenerative medicines," said Li Qing, General
Manager, GE Healthcare Life Sciences, Greater China.
Read this release in full at http://www.investorideas.com/news/2017/biotech/04131CBMG.asp
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. (CBMG) develops
proprietary cell therapies for the treatment of cancer and degenerative
diseases. We conduct immuno-oncology and stem cell clinical trials in China
using products from our integrated GMP laboratory. Our GMP facilities in China,
consisting of twelve independent cell production lines, are designed and
managed according to both China and U.S. GMP standards. CBMG recently
commenced two Phase I human clinical trials in China using CAR-T to treat
relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia (ALL) and
Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I
trial in China for AlloJoinTM (CBMG`s "Off-the-Shelf" Allogeneic
Human Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee
Osteoarthritis (KOA). CBMG was also recently awarded $2.29 million from the
California Institute for Regenerative Medicine (CIRM) to support pre-clinical
studies of AlloJoinTM for Knee Osteoarthritis in the United States. To learn
more about CBMG, please visit www.cellbiomedgroup.com.
About GE Healthcare
GE Healthcare provides transformational medical
technologies and services to meet the demand for increased access, enhanced
quality and more affordable healthcare around the world. GE (GE) works on
things that matter - great people and technologies taking on tough challenges.
From medical imaging, software & IT, patient monitoring and diagnostics to
drug discovery, biopharmaceutical manufacturing technologies and performance
improvement solutions, GE Healthcare helps medical professionals deliver great
healthcare to their patients. For more information about GE Healthcare, visit
our website at www.gehealthcare.com.
Forward-Looking Statements
This press release contains forward-looking
statements-including descriptions of plans, strategies, trends, specific
activities, investments and other non-historical facts-as defined by the
Private Securities Litigation Reform Act of 1995, Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Forward-looking information is inherently uncertain, and
actual results could differ materially from those anticipated due to a number
of factors, which include risks inherent in doing business, trends affecting
the global economy (including the devaluation of the RMB by China in August
2015), and other risks detailed in CBMG`s reports filed with the Securities and
Exchange Commission, quarterly reports on form 10-Q, current reports on form
8-K and annual reports on form 10-K. Forward-looking statements may be
identified by terms such as "may," "will,"
"expects," "plans," "intends,"
"estimates," "potential," "continue" or similar
terms or their negations. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot guarantee that
future results, levels of activity, performance or achievements will be
obtained. CBMG does not have any obligation to update these forward-looking
statements other than as required by law.
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 408-973-7884
Vivian Chen
Managing Director Investor Relations, Citigate Dewe
Rogerson
+1 347 481-3711
BiotechIndustryStocks.com - investing ideas in
biotechnology stocks, medical technology and life sciences
Like Biotech Stocks? View our Biotech Stocks Directory
Get
News Alerts on Biotech Stocks
Disclaimer/Disclosure: Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated for
news publication and distribution, social media and marketing, content creation
and more. Contact each company directly regarding content and press release
questions. Disclosure is posted for each compensated news release, content
published /created if required but otherwise the news was not compensated for
and was published for the sole interest of our readers and followers. More
disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
No comments:
Post a Comment